1
|
García-Chávez J, Hernández-Juárez J, Sánchez-Jara B, García-Lee MT, Rodríguez-Castillejos C, Montiel-Cervantes L, Moreno-Hernández M, Ramos-Blas GJ, Soto-Padilla JM, Flores-Villegas LV, Pérez-Zúñiga JM, López-Arroyo JL, Villarreal-Martínez L, Madera-Maldonado CE, Herrejón-Carmona M, Lozano-Garcidueñas M, Vargas-Ruiz ÁG, Hernández-Hernández D, de la Peña-Díaz A, Aquino-Fernández E, Majluf-Cruz A. Consenso mexicano para el diagnóstico y tratamiento de la trombastenia de Glanzmann. GAC MED MEX 2022. [DOI: 10.24875/gmm.m22000691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
|
2
|
Flores-García M, Fernández-González JM, León-Martínez M, Hernández-Ortega S, Hernández-López JR, Reyes-Munguía D, Sánchez-Sarabia H, Piña-Fragoso Z, de la Peña-Díaz A. Tyrame [N-(3-hydroxy-1:3:5(10)-estratrien-17b-yl)-4-hydroxyphenethylamine], antithrombotic aminoestrogen that decreases microvesicle formation. GAC MED MEX 2022; 157:588-593. [DOI: 10.24875/gmm.m21000621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
3
|
Echenagucía-Echenagucía M, Trueba-Gómez R, Rosenfeld-Mann F, Zavala-Hernández C, Martínez-Murillo C, de la Peña-Díaz A. Parámetros de laboratorio de importancia en el manejo de pacientes con COVID-19. GAC MED MEX 2022. [DOI: 10.24875/gmm.m21000489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
4
|
Flores-García M, Fernández-González JM, León-Martínez M, Hernández-Ortega S, Hernández-López JR, Reyes-Munguía D, Sánchez-Sarabia H, Piña-Fragoso Z, de la Peña-Díaz A. Tyrame [N-(3-hidroxi-1:3:5(10)-estratrien-17β-il)-4-hidroxifenetilamina], aminoestrógeno antitrombótico que disminuye la formación de microvesículas. GAC MED MEX 2021. [DOI: 10.24875/gmm.21000201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
5
|
Jiménez-Orozco FA, Galicia-Zapatero S, López-López E, Medina-Franco JL, Cedeño FL, Flores-García M, Mejia-Domínguez A, de la Peña-Díaz A. Monosubstituted Coumarins Inhibit Epinephrine-Induced Platelet Aggregation Antiplatelet Effect of Monosubstituted Coumarins. Cardiovasc Hematol Agents Med Chem 2021; 20:43-51. [PMID: 33906594 PMCID: PMC9127734 DOI: 10.2174/1871525719666210427132808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Revised: 03/15/2021] [Accepted: 03/29/2021] [Indexed: 11/22/2022]
Abstract
Aim The aim of this study was to evaluate the in vitro effect of coumarin and 15 monosubstituted derivatives on the inhibition of human platelet aggregation induced by various pro-aggregatory agonists, particularly by epinephrine. Background The emergence of residual platelet reactivity during the use of conventional antiplatelet agents (acetylsalicylic acid and clopidogrel) is one of the main causes of double therapy´s therapeutic failure. Platelet adrenoceptors participate in residual platelet reactivity. Therefore, it is necessary to develop new antiplatelet agents that inhibit epinephrine-induced platelet aggregation as a new therapeutic strategy. Information on the antiplatelet activity of coumarins in inhibiting epinephrine-induced aggregation is limited. Objective The objective of this study was to establish the structure-activity relationship (SAR) of coumarin derivatives with hydroxy, methoxy, and acetoxy groups in different positions of the coumarin nucleus to identify the most active molecules. Moreover, this study aimed to use in silico studies to suggest potential drug targets to which the molecules bind to produce antiplatelet effects. Methods The platelet aggregation was performed using a Lumi-aggregometer; the inhibitory activity of 16 compounds were evaluated by inducing the aggregation of human platelets (250 × 103/μl) with epinephrine (10 µM), collagen (2 µg/ml) or ADP (10 µM). The aggregation of control platelets was considered 100% of the response for each pro-aggregatory agonist. Results Eleven molecules inhibited epinephrine-induced aggregation, with 3-acetoxycoumarin and 7-methoxycoumarin being the most active. Only coumarin inhibited collagen-induced platelet aggregation, but no molecule showed activity when using ADP as an inducer. Conclusions In silico studies suggest that most active molecules might have antagonistic interactions in the α2 and β2 adrenoceptors. The antiplatelet actions of these coumarins have the potential to reduce residual platelet reactivity and thus contribute to the development of future treatments for patients who do not respond adequately to conventional agents.
Collapse
Affiliation(s)
- Fausto Alejandro Jiménez-Orozco
- Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán 04510, CDMX. Mexico
| | - Sergio Galicia-Zapatero
- Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán 04510, CDMX. Mexico
| | - Edgar López-López
- Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán 04510, CDMX. Mexico
| | - José L Medina-Franco
- Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán 04510, CDMX. Mexico
| | - Fernando León Cedeño
- Departamento de Química Orgánica, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán 04510, CDMX. Mexico
| | - Mirthala Flores-García
- Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Tlalpan 14080, CDMX. Mexico
| | - Ana Mejia-Domínguez
- Banco de Sangre, Instituto Nacional de Cardiología Ignacio Chávez, Tlalpan 14080, CDMX. Mexico
| | - Aurora de la Peña-Díaz
- Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán 04510, CDMX. Mexico
| |
Collapse
|
6
|
González-Villalva A, de la Peña-Díaz A, Rojas-Lemus M, López-Valdez N, Ustarroz-Cano M, García-Peláez I, Bizarro-Nevares P, Fortoul TI. Fisiología de la hemostasia y su alteración por la coagulopatía en COVID-19. Rev Fac Med 2020. [DOI: 10.22201/fm.24484865e.2020.63.5.08] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
COVID-19 global pandemic caused by Sars-CoV-2 virus, has worried to health care providers due to the high mortality rate related to coagulopathy in many patients. COVID-19 coagulopathy is mainly thrombotic, first locally in lungs but later on it becomes micro and macrovascular systemic coagulopathy. It has been associated to endothelial damage, inflammation, neutrophil-extracellular traps, monocyte and macrophage activation, cytokines storm that induce a vicious cycle of thrombosis and inflammation. The increased levels of prothrombotic factors as tissue factor, Von Willebrand factor, fibrinogen, VIII factor and the decreased levels of antithrombotic factos, such as: antithrombin and Protein S have been reported in COVID-19 patients. Insufficiency of fibrinolysis because of the increased levels of PAI-1 (plasminogen activator inhibitor 1) have been reported also. During this disease there are intraalveolar fibrin deposits that needs to be degraded. Fibrinolysis of thrombus and fibrin intraalveolar degradation are responsible for the high increase of D-dimers levels that are an important predictor of severity of the disease. In this report, the physiology of hemostasis, thromboinflamation secondary to Sars-CoV-2 infection are reviewed, as well as the clinical evidence and the physiopathology of COVID-19 coagulopathy from the basic sciences point of view.
Keywords:Hemostasis; coagulation; thrombosis; coagulopathy; Sars-CoV-2; COVID-19.
Collapse
Affiliation(s)
- Adriana González-Villalva
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina UNAM.Departamento de Biología Celular. Ciudad de México, México
| | - Aurora de la Peña-Díaz
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina. Departamento de Farmacología. Ciudad de México. México; Secretaría de Salud (Ssa).Instituto Nacional de Cardiología “Ignacio Chávez”. Sede Periférica.Laboratorio de Trombosis y Fibrinolisis. Ciudad de México, México
| | - Marcela Rojas-Lemus
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina UNAM.Departamento de Biología Celular. Ciudad de México, México
| | - Nelly López-Valdez
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina UNAM.Departamento de Biología Celular. Ciudad de México, México
| | - Martha Ustarroz-Cano
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina UNAM.Departamento de Biología Celular. Ciudad de México, México
| | - Isabel García-Peláez
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina UNAM.Departamento de Biología Celular. Ciudad de México, México
| | - Patricia Bizarro-Nevares
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina UNAM.Departamento de Biología Celular. Ciudad de México, México
| | - Teresa I. Fortoul
- Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina UNAM.Departamento de Biología Celular. Ciudad de México, México; Universidad Nacional Autónoma de México (UNAM). Facultad de Medicina. Revista de la Facultad de Medicina. Editora. Ciudad de México. México
| |
Collapse
|
7
|
Valente-Acosta B, Flores-García M, González-Zárate G, Gerson-Cwilich R, Maldonado-Méndez M, Juárez-Vega G, Anglés-Cano E, Peña-Díaz ADL. Fibrinolytic Activity of Circulating Microvesicles Is Associated with Progression of Breast Cancer. TOHOKU J EXP MED 2020; 250:121-128. [PMID: 32115494 DOI: 10.1620/tjem.250.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The fibrinolytic system plays an important role in breast cancer, favoring progression through extracellular-matrix degradation, angiogenesis, apoptosis and cellular proliferation. The expression of urokinase-type plasminogen activator (uPA) in breast cancer tissue is widely recognized as an unfavorable prognostic factor. However, fibrinolytic activity associated with uPA cannot be reliably measured in the blood because of the rapid inhibition of uPA by plasminogen activator inhibitor-1 (PAI-1). By contrast, circulating microvesicles (Mvs) in peripheral blood protect bound enzymes from inhibition. Mvs are extracellular vesicles, released from various types of cells, and their size fluctuates between 100 and 1,000 nm. Mvs carry DNA, RNA, miRNA, and proteins, thereby serving as a source of horizontal communication between cells. We investigated whether fibrinolytic activity on circulating Mvs reflects breast cancer progression. The study population consisted of 13 patients with breast cancer and 13 healthy women. The cancer patients included 4 patients in remission, 3 patients with locally advanced cancer, and 6 with metastatic disease. Mvs were isolated from peripheral blood, quantified by a protein concentration method, and their fibrinolytic potential was measured by their capacity to generate plasmin. Although the quantity of Mvs found in patients with cancer and healthy individuals was similar, plasmin generated on Mvs was twice the amount in patients with metastasis than in healthy women (P < 0.05), underlying the value of this distinctive parameter. The data suggest that in breast cancer patients, higher fibrinolytic activity of circulating Mvs could be related to progression and metastasis of breast cancer.
Collapse
Affiliation(s)
- Benjamín Valente-Acosta
- Departamento de Medicina Interna y Centro de Cáncer, The American British Cowdray Medical Center
| | | | | | - Raquel Gerson-Cwilich
- Departamento de Medicina Interna y Centro de Cáncer, The American British Cowdray Medical Center
| | - Marai Maldonado-Méndez
- Laboratorio de Trombosis y Fibrinolisis, Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México
| | - Guillermo Juárez-Vega
- Unidad de Citometría de Flujo, Red de Apoyo a la Investigación, Coordinación de Investigación Científica, Universidad Nacional Autónoma de México.,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
| | | | - Aurora de la Peña-Díaz
- Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez.,Laboratorio de Trombosis y Fibrinolisis, Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México
| |
Collapse
|
8
|
Camacho-Mejorado R, Gómez R, Torres-Sánchez LE, Alhelí Hernández-Tobías E, Noris G, Santana C, Magaña JJ, Orozco L, de la Peña-Díaz A, de la Luz Arenas-Sordo M, Antonio Meraz-Ríos M, Majluf-Cruz A. Correction to ' ALOX5, LPA, MMP9 and TPO gene polymorphisms increase atherothrombosis susceptibility in middle-aged Mexicans'. R Soc Open Sci 2020; 7:200167. [PMID: 32257362 PMCID: PMC7062107 DOI: 10.1098/rsos.200167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
[This corrects the article DOI: 10.1098/rsos.190775.].
Collapse
|
9
|
Camacho-Mejorado R, Gómez R, Torres-Sánchez LE, Alhelí Hernández-Tobías E, Noris G, Santana C, Magaña JJ, Orozco L, de la Peña-Díaz A, de la Luz Arenas-Sordo M, Meraz-Ríos MA, Majluf-Cruz A. ALOX5, LPA, MMP9 and TPO gene polymorphisms increase atherothrombosis susceptibility in middle-aged Mexicans. R Soc Open Sci 2020; 7:190775. [PMID: 32218930 PMCID: PMC7029922 DOI: 10.1098/rsos.190775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Accepted: 11/28/2019] [Indexed: 06/10/2023]
Abstract
Atherothrombosis is the cornerstone of cardiovascular diseases and the primary cause of death worldwide. Genetic contribution to disturbances in lipid metabolism, coagulation, inflammation and oxidative stress increase the susceptibility to its development and progression. Given its multifactorial nature, the multiloci studies have been proposed as potential predictors of susceptibility. A cross-sectional study was conducted to explore the contribution of nine genes involved in oxidative stress, inflammatory and thrombotic processes in 204 subjects with atherothrombosis matched by age and gender with a healthy group (n = 204). To evaluate the possibility of spurious associations owing to the Mexican population genetic heterogeneity as well as its ancestral origins, 300 unrelated mestizo individuals and 329 Native Americans were also included. ALOX5, LPA, MMP9 and TPO gene polymorphisms, as well as their multiallelic combinations, were twice to four times more frequent in those individuals with clinical manifestations of atherothrombosis than in the healthy group. Once adjusting for population stratification was done, these differences remained. Our results add further evidence on the contribution of ALOX5, LPA, MMP9 and TPO polymorphisms to atherothrombosis development in the middle-aged group, emphasizing the multiethnic studies in search of gene risk polymorphisms.
Collapse
Affiliation(s)
| | - Rocío Gómez
- Departamento de Toxicología, Cinvestav-IPN, Mexico City 07360, Mexico
| | - Luisa E. Torres-Sánchez
- Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico
| | | | - Gino Noris
- Laboratorio Biología Molecular Diagnóstica, Querétaro, Qro, Mexico
| | - Carla Santana
- Laboratorio Biología Molecular Diagnóstica, Querétaro, Qro, Mexico
| | | | - Lorena Orozco
- Laboratorio de Inmunogenómica y Enfermedades Metabólicas, INMEGEN, Mexico City, Mexico
| | - Aurora de la Peña-Díaz
- Facultad de Medicina, Departamento de Farmacología, Universidad Nacional Autónoma de México, Mexico
- Departamento de Biología Molecular, Instituto Nacional de Cardiología, Mexico City, Mexico
| | | | | | - Abraham Majluf-Cruz
- Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, IMSS, Mexico City, Mexico
| |
Collapse
|
10
|
Román-Anguiano NG, Correa F, Cano-Martínez A, de la Peña-Díaz A, Zazueta C. Cardioprotective effects of Prolame and SNAP are related with nitric oxide production and with diminution of caspases and calpain-1 activities in reperfused rat hearts. PeerJ 2019; 7:e7348. [PMID: 31392096 PMCID: PMC6673759 DOI: 10.7717/peerj.7348] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Accepted: 06/25/2019] [Indexed: 01/26/2023] Open
Abstract
Cardiac tissue undergoes changes during ischemia-reperfusion (I-R) that compromise its normal function. Cell death is one of the consequences of such damage, as well as diminution in nitric oxide (NO) content. This signaling molecule regulates the function of the cardiovascular system through dependent and independent effects of cyclic guanosine monophosphate (cGMP). The independent cGMP pathway involves post-translational modification of proteins by S-nitrosylation. Studies in vitro have shown that NO inhibits the activity of caspases and calpains through S-nitrosylation of a cysteine located in their catalytic site, so we propose to elucidate if the regulatory mechanisms of NO are related with changes in S-nitrosylation of cell death proteins in the ischemic-reperfused myocardium. We used two compounds that increase the levels of NO by different mechanisms: Prolame, an amino-estrogenic compound with antiplatelet and anticoagulant effects that induces the increase of NO levels in vivo by activating the endothelial nitric oxide synthase (eNOS) and that has not been tested as a potential inhibitor of apoptosis. On the other hand, S-Nitroso-N-acetylpenicillamine (SNAP), a synthetic NO donor that has been shown to decrease cell death after inducing hypoxia-reoxygenation in cell cultures. Main experimental groups were Control, I-R, I-R+Prolame and I-R+SNAP. Additional groups were used to evaluate the NO action pathways. Contractile function represented as heart rate and ventricular pressure was evaluated in a Langendorff system. Infarct size was measured with 2,3,5-triphenyltetrazolium chloride stain. NO content was determined indirectly by measuring nitrite levels with the Griess reaction and cGMP content was measured by Enzyme-Linked ImmunoSorbent Assay. DNA integrity was evaluated by DNA laddering visualized on an agarose gel and by Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling assay. Activities of caspase-3, caspase-8, caspase-9 and calpain-1 were evaluated spectrophotometrically and the content of caspase-3 and calpain-1 by western blot. S-nitrosylation of caspase-3 and calpain-1 was evaluated by labeling S-nitrosylated cysteines. Our results show that both Prolame and SNAP increased NO content and improved functional recovery in post-ischemic hearts. cGMP-dependent and S-nitrosylation pathways were activated in both groups, but the cGMP-independent pathway was preferentially activated by SNAP, which induced higher levels of NO than Prolame. Although SNAP effectively diminished the activity of all the proteases, a correlative link between the activity of these proteases and S-nitrosylation was not fully established.
Collapse
Affiliation(s)
| | - Francisco Correa
- Departamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiologia Ignacio Chávez, México, México
| | - Agustina Cano-Martínez
- Departamento de Fisiología, Instituto Nacional de Cardiologia Ignacio Chávez, México, México
| | - Aurora de la Peña-Díaz
- Departamento de Biología Molecular, Instituto Nacional de Cardiologia Ignacio Chávez, México, México.,Departamento de Farmacología, Universidad Nacional Autónoma de México, México, Mexico
| | - Cecilia Zazueta
- Departamento de Biomedicina Cardiovascular, Instituto Nacional de Cardiologia Ignacio Chávez, México, México
| |
Collapse
|
11
|
Flores-García M, Fernández-G JM, Busqueta-Griera C, Gómez E, Hernández-Ortega S, Lamothe-Flores JCD, Gómez-Vidales V, Mejía-Domínguez AM, Anglés-Cano E, de la Peña-Díaz A. New Copper Compounds with Antiplatelet Aggregation Activity. Med Chem 2019; 15:850-862. [PMID: 30799791 DOI: 10.2174/1573406415666190222123207] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 01/26/2019] [Accepted: 02/07/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND Ischemic heart disease, cerebrovascular accident, and venous thromboembolism have the presence of a thrombotic event in common and represent the most common causes of death within the population. OBJECTIVE Since Schiff base copper(II) complexes are able to interact with polyphosphates (PolyP), a procoagulant and potentially prothrombotic platelet agent, we investigated the antiplatelet aggregating properties of two novel tridentate Schiff base ligands and their corresponding copper( II) complexes. METHODS The Schiff base ligands (L1) and (L2), as well as their corresponding copper(II) complexes (C1) and (C2), were synthesized and characterized by chemical analysis, X-ray diffraction, mass spectrometry, and UV-Visible, IR and far IR spectroscopy. In addition, EPR studies were carried out for (C1) and (C2), while (L1) and (L2) were further analyzed by 1H and 13C NMR. Tests for antiplatelet aggregation activities of all of the four compounds were conducted. RESULTS X-ray diffraction studies show that (L1) and (L2) exist in the enol-imine tautomeric form with a strong intramolecular hydrogen bond. NMR studies show that both ligands are found as enol-imine tautomers in CDCl3 solution. In the solid state, the geometry around the copper(II) ion in both (C1) and (C2) is square planar. EPR spectra suggest that the geometry of the complexes is similar to that observed in the solid state by X-ray crystallography. Compound (C2) exhibited the strongest antiplatelet aggregation activity. CONCLUSION Schiff base copper(II) complexes, which are attracting increasing interest, could represent a new approach to treat thrombosis by blocking the activity of PolyP with a potential anticoagulant activity and, most importantly, demonstrating no adverse bleeding events.
Collapse
Affiliation(s)
- Mirthala Flores-García
- Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano 1, Tlalpan 14080, Ciudad de México, Mexico
| | - Juan Manuel Fernández-G
- Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, Ciudad de México, Mexico
| | - Cristina Busqueta-Griera
- Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, Ciudad de México, Mexico
| | - Elizabeth Gómez
- Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, Ciudad de México, Mexico
| | - Simón Hernández-Ortega
- Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, Ciudad de México, Mexico
| | | | - Virginia Gómez-Vidales
- Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, Ciudad de México, Mexico
| | - Ana María Mejía-Domínguez
- Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano 1, Tlalpan 14080, Ciudad de México, Mexico
| | - Eduardo Anglés-Cano
- INSERM UMR-S1140, Faculty of Sciences, Pharmaceutiques & Biologiques, Avenue de l'Observatoire, 75270 Paris, Cedex 06, France
| | - Aurora de la Peña-Díaz
- Instituto Nacional de Cardiología "Ignacio Chávez", Juan Badiano 1, Tlalpan 14080, Ciudad de México, Mexico.,Facultad de Medicina, Departamento de Farmacología, Universidad Nacional Autónoma de México, Circuito Escolar, Ciudad Universitaria, Coyoacán 04510, Ciudad de México, México
| |
Collapse
|
12
|
Pérez-Hernández N, Vargas-Alarcón G, Martínez-Rodríguez N, Martínez-Ríos MA, Peña-Duque MA, Peña-Díaz ADL, Valente-Acosta B, Posadas-Romero C, Medina A, Rodríguez-Pérez JM. The matrix metalloproteinase 2-1575 gene polymorphism is associated with the risk of developing myocardial infarction in Mexican patients. J Atheroscler Thromb 2012; 19:718-27. [PMID: 22785600 DOI: 10.5551/jat.11817] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
AIM Was to evaluate the role of seven matrix metalloproteinase (MMP) polymorphisms in the genetic susceptibility to develop myocardial infarction in Mexican individuals. METHODS Seven polymorphisms in the MMP genes were genotyped by 5' exonuclease TaqMan genotyping assays in 300 patients with myocardial infarction and 300 healthy unrelated controls. RESULTS A similar distribution of MMP2-1306 (rs243865), MMP2-790 (rs243864), MMP2-735 (rs22850553), MMP7-153(rs11568819), MMP7-181(rs11568818), and MMP12-82(rs2276109) polymorphisms was observed in both studied groups. On the other hand, patients showed increased frequencies of MMP2-1575 A allele and AA genotype when compared to controls (pC= 0.001; OR= 1.58 and pC= 0.036; OR= 2.37, respectively). According to the dominant model, individuals with AG+AA genotypes had a 1.65-fold increased risk of developing the disease (p= 0.002). After adjusting for known risk factors, we found a significant contribution of gender, BMI, smoking habit, diabetes mellitus, and hypertension to the inheritance model. In this analysis, individuals with the-1575 AA genotype had a 4.23-fold increased risk of developing MI (p= 0.003). On the other hand, an association of the MMP12-82 polymorphism with the extent of coronary artery disease (CAD) was observed. In our study, it was possible to distinguish two risk haplotypes and one protective haplotype for this disease in the MMP2 gene. CONCLUSIONS The results suggest that the MMP2-1575 (rs243866) gene polymorphism could be involved in the risk of developing myocardial infarction in Mexican individuals.
Collapse
Affiliation(s)
- Nonanzit Pérez-Hernández
- Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Flores-García M, Fernández-G JM, León-Martínez M, Hernández-Ortega S, Pérez-Méndez O, Correa-Basurto J, Carreón-Torres E, Tolentino-López LE, Ceballos-Reyes GM, de la Peña-Díaz A. The structures and inhibitory effects of Buame [N-(3-hydroxy-1,3,5(10)-estratrien-17β-yl)-butylamine] and Diebud [N,N'-bis-(3-hydroxy-1,3,5(10)-estratrien-17β-yl)-1,4-butanediamine] on platelet aggregation. Steroids 2012; 77:512-20. [PMID: 22326683 DOI: 10.1016/j.steroids.2012.01.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Revised: 01/13/2012] [Accepted: 01/14/2012] [Indexed: 10/25/2022]
Abstract
Compounds with estrogenic effects that also inhibit platelet aggregation might be useful in reducing thrombotic events associated with estrogenic therapy. In this study, two aminoestrogens, Buame [N-(3-hydroxy-1,3,5(10)-estratrien-17β-yl)-butylamine] and Diebud [N,N'-bis-(3-hydroxy-1,3,5(10)-estratrien-17β-yl)-1,4-butanediamine], were synthesized and characterized using common analytical methods and spectrophotometric analyses. The location and orientation of these molecules on the estrogenic receptor α (ERα) were also evaluated. Platelet inhibitory effects were elucidated ADP-induced platelet aggregation and ADP- and collagen-induced ATP release. Molecular docking demonstrated that Buame can reach and bind to the ERα in the ligand binding domain (LBD) similar to 17β-estradiol (co-crystallized ligand). On the other hand, Diebud binds only to the surface of ERα due to its high molecular volume compared to 17β-estradiol and Buame.
Collapse
Affiliation(s)
- Mirthala Flores-García
- Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chavéz, México D.F., Mexico
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Peña-Duque MA, Baños-González MA, Valente-Acosta B, Rodríguez-Lobato LG, Martínez-Ríos MA, Cardoso-Saldaña G, Barragán-García R, Herrera-Alarcón V, Linares-López C, Delgado-Granados H, de la Peña-Díaz A. Homocysteine is related to aortic mineralization in patients with ischemic heart disease. J Atheroscler Thromb 2012; 19:292-7. [PMID: 22240908 DOI: 10.5551/jat.10157] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
UNLABELLED Homocysteine is implicated as an early atherosclerotic promoter, which enhances the smooth muscle cell proliferation and produces free radicals that induce cellular damage. These factors must have a role in the progression of atherosclerosis that subsequently leads to vascular mineralization. AIM Identify a correlation between the plasma concentration of total homocysteine and the amount of minerals that accumulate in the aorta of patients with atherosclerosis. METHODS We performed a cross-sectional study in 13 patients with three-vessel coronary artery disease, undergoing coronary artery bypass surgery. Aortic and mammary artery specimens were analyzed using a scanning electron microscope with an energy dispersive X-ray spectrometer. The homocysteine was determined using an immunonephelometry method. RESULTS The amount of minerals in the aorta was greater (300 ± 181.6 particles per 500 µm2 than that in the mammary artery (64 ± 45 particles per 500 µm2 (p < 0.01). The average tHcy was 9.5 ± 2.3 µmol/L. The Spearman's rank correlation coefficient was positive between tHcy, and aortic iron (p < 0.05). CONCLUSIONS Our study demonstrates that the aorta is dramatically affected by mineralization compared to the mammary artery. In addition, a direct correlation was identified between the levels of tHcy and the iron particles in the aortic wall.
Collapse
Affiliation(s)
- Marco A Peña-Duque
- Instituto Nacional de Cardiología Ignacio Chávez, Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Cirugía, Mexico
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Baños-González MA, Anglés-Cano E, Cardoso-Saldaña G, Peña-Duque MA, Martínez-Ríos MA, Valente-Acosta B, González-Pacheco H, Peña-Díaz ADL. Lipoprotein(a) and Homocysteine Potentiate the Risk of Coronary Artery Disease in Male Subjects. Circ J 2012; 76:1953-7. [DOI: 10.1253/circj.cj-12-0039] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Manuel Alfonso Baños-González
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Hospital Regional de Alta Especialidad "Juan Graham Casasús", Departamento de Cardiología
- Universidad Juárez Autónoma de Tabasco
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Hospital Regional de Alta Especialidad "Juan Graham Casasús", Departamento de Cardiología
| | - Eduardo Anglés-Cano
- Institut National de la Sante et de la Recherche Médicale, U919 Serine Proteases in Neurovascular Pathology
- Institut National de la Sante et de la Recherche Médicale, U919 Serine Proteases in Neurovascular Pathology
| | - Guillermo Cardoso-Saldaña
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
| | - Marco Antonio Peña-Duque
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
| | - Marco Antonio Martínez-Ríos
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
| | - Benjamin Valente-Acosta
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Facultad de Medicina, Departamento de Farmacología, Universidad Nacional Autónoma de México
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Facultad de Medicina, Departamento de Farmacología, Universidad Nacional Autónoma de México
| | - Héctor González-Pacheco
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
| | - Aurora de la Peña-Díaz
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Facultad de Medicina, Departamento de Farmacología, Universidad Nacional Autónoma de México
- Instituto Nacional de Cardiología "Ignacio Chávez", Grupo Genética Intervencionista, Departamentos de Biología Molecular, Hemodinámica, Endocrinología, Unidad Coronaria, Juan Badiano 1
- Facultad de Medicina, Departamento de Farmacología, Universidad Nacional Autónoma de México
| |
Collapse
|
16
|
Montiel-Manzano G, de la Peña-Díaz A, Majluf-Cruz A, Cesarman-Maus G, Corona-de la Peña N, Cruz-Cruz D, Gaminio E, Martínez-Murillo C, Mayagoitia T, Miranda-Peralta E, Poblete T, Quintana-Martínez S, Ramírez R, Razo D, Ruiz de Chávez-Ochoa A, Reyes-Núñez VA, Salazar R, Vicencio-Santiago GV, Villa R, Reyes-Núñez AV. [National evaluation of the diagnosis of activated protein C resistance]. Rev Invest Clin 2003; 55:358-69. [PMID: 14515684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Thrombophilia or prothrombotic state appears when activation of blood hemostatic mechanisms overcomes the physiological anticoagulant capacity allowing a thrombotic event. Thrombosis is the leading worldwide mortality cause and due to its high associated morbidity and mortality, it should be insisted in the opportune identification of a thrombophilic state. The study of thrombophilia identifies individuals at high risk for thrombosis. This meeting was conceived first to analyze the current status of the diagnosis of thrombophilia in Mexico and second to create the base for a national consensus for thrombophilia screening and for the establishment of a national center for laboratory reference and quality control for thrombophilia. Since searching of activated protein C resistance (APCR) and FV Leiden seem to have priority either in the clinical setting and in public health services, it was decided to start with these two abnormalities as a model to analyze the current status of thrombophilia diagnosis in the clinical laboratory. At this time, several thrombophilic abnormalities have been described however, APCR remains the most important cause of thrombophilia, accounting for as much as 20% to 60% of all venous thrombosis. APCR is a consequence of the resistance of activated FV to be inactivated by activated protein C. Procoagulant activity of activated FV increases the risk of thrombosis. Hereditary APCR is almost always due to a point mutation at the nucleotide 1691 of the FV gen inducing an Arg506Glu substitution in FV molecule. This mutation is better known as FV Leiden. Heterocygous carriers of FV Leiden have a thrombotic risk 5 to 10 times higher than general population while the risk for the homocygote state is increased 50 to 100-fold. When activated PC is added to plasma from patients with FV Leiden, this last resists the anticoagulant effect of activated PC. Therefore, thrombin production is not inhibited. This phenomenon is called APCR. The functional test evaluates the partially activated thromboplastin time (aPTT) in a plasma sample before and after adding activated PC. The result is reported as a standardized sensibility index: aPTT post-activated PC/aPTT pre-activated PC. The conclusions of this national reunion pretend to optimize the available resources in our country in order to allow a wide and less-expensive diagnosis of patients with thrombosis.
Collapse
|